Flutamide (2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-
propanamide) is a nonsteroidal antiandrogen used for the treatment of prostate carcinoma. However, its therapeutic activity is compromised because of potential liver toxicity. Among 1091 patients treated for prostate cancer with flutamide, the incidence of liver toxicity (defined as Ͼ4-fold increase in serum transaminase activity) was 0.36%. 1) In addition, Wada et al. reported that the incidence of liver disorder (defined as Ͼ1.5-fold increase in alanine aminotransferase levels) was 26%.
2) Furthermore, between February 1989 and December 1994, the Food and Drug Administration received reports of 20 deaths and 26 hospitalizations due to hepatotoxicity secondary to flutamide. 3) Flutamide-induced hepatitis may be cholestatic and/or cytolytic, and fulminant hepatitis can occur. [4] [5] [6] [7] [8] Fau et al. proposed that cytochrome P450-mediated generation of electrophilic metabolites may play a role in flutamide-induced cytolytic hepatitis, based on studies in isolated rat hepatocytes. 9 ) Furthermore, Wang et al. reported that flutamide and hydroxyflutamide (a major metabolite of flutamide) are cytotoxic to primary cultured rat hepatocytes at concentrations of approximately 40 mM and 170 mM, respectively. 10) However, little is yet known about the mechanism leading to cholestatic hepatitis. Therefore, this was the focus of the present study.
Cholestasis, defined as impairment of bile formation, is accompanied with retention of bile salts, and the resulting intracellular accumulation of bile salts causes cell damage through a direct effect on trafficking of Fas to the cell surface, leading to apoptosis. 11, 12) It was reported that mutation of the human bile salt export pump (BSEP, ABCB11) gene causes progressive intrahepatic cholestasis. 13, 14) Several drugs such as troglitazone, bosentan, and cyclosporine A induce cholestatic hepatitis, probably by inhibiting BSEP-mediated taurocholic acid transport. [15] [16] [17] BSEP is the transport protein primary responsible for biliary excretion of unconjugated bile salts, which are more hepatotoxic than their amino acid (i.e. taurine and glycine) conjugated metabolites. 18) It is known that flutamide-induced hepatotoxicity is ameliorated by ursodeoxycholic acid (UDCA). 19) Since UDCA is a ligand of farnesoid X receptor (FXR) and FXR up-regulates BSEP activity, it was proposed that the action of UDCA is associated with a change in the expression level of BSEP. 20) Furthermore, Fickert et al. reported that protein level of Bsep was increased in UDCA treated mice. 21 ) Therefore, we examined the role of BSEP in flutamide-related cholestatic hepatitis. We also examined the effect of hydroxyflutamide, since hydroxyflutamide is cytotoxic 10) and its plasma concentration is much higher than that of flutamide. 22) Flutamide and hydroxyflutamide are metabolized to FLU-1 and FLU-3, and their glucuronides, 22, 23) but flutamide-induced cholestasis may not involve these metabolites, since no consistent differences were found in serum levels of these metabolites, including the glucuronides, between patients with normal function and those suffering hepatic dysfunction. 24) Therefore, in the present study, we focused on the effects of flutamide itself and hydroxyflutamide. The non-steroidal antiandrogen flutamide is widely used for treatment of prostatic cancer, but causes side effects, including cholestatic hepatitis and fulminant hepatitis. We investigated the pathogenesis of flutamide-induced cholestatic hepatitis, focusing on the bile salt export pump (BSEP; ABCB11), which exports bile salts to the bile. We examined the inhibitory effects of flutamide and its active metabolite, hydroxyflutamide, on the transport of taurocholic acid (TCA) by membrane vesicles derived from hBSEP-expressing Sf9 cells. Flutamide inhibited the transport of TCA by hBSEP (IC 50 value, about 50 m mM), while hydroxyflutamide had no effect at up to 100 m mM. When flutamide was administered to rats as a single oral dose of 100 mg/kg, the biliary excretion rate of bolus-injected [ Mg(NO 3 ) 2 and 50 mM sucrose, pH 7.4), and passed through a 25-gauge needle (30 times). Flutamide, hydroxyflutamide and cyclosporine A were each dissolved in dimethylsulfoxide (DMSO; final concentration 1%), and DMSO without inhibitors was included as a control. After preincubation of the membrane vesicles for 2 min, uptake of [ 3 H]TCA was initiated by the addition of a 90 ml aliquot of transport buffer containing [ 3 H]taurocholic acid, 5 mM adenosine triphosphate (ATP) or 5 mM adenosine monophosphate (AMP), an ATPregenerating system (10 mM creatine phosphate and 100 mg/ml creatine phosphokinase), and inhibitors to 10 ml of membrane vesicles (10 mg protein) at 37°C. At designated times, the uptake was terminated by the addition of 1 ml of ice-cold stop buffer (10 mM Hepes, 150 mM KNO 3 , 10 mM Mg(NO 3 ) 2 , 50 mM sucrose, 0.1 mM TCA, pH 7.4). To terminate the reactions, the mixture was filtered through a HA filter (0.45 mm; Millipore Corp., Bedford, MA, U.S.A.), and then washed twice with 5 ml of ice-cold stop buffer. Specific uptake by BSEP was evaluated as ATP-dependent uptake, obtained as the difference between the uptakes in the presence of ATP and of AMP. The radioactivity retained on the filter and in the reaction mixture was measured with a liquid scintillation counter (Perkin Elmer, Boston, MA, U.S.A.) after the addition of scintillation cocktail, Clearsol I ® (Nacalai Tesque, Kyoto, Japan).
MATERIALS AND METHODS

Chemicals
In the present study, we also examined the irreversible inhibitory effect on hBSEP-mediated uptake of [ In Vivo Study Male Wistar rats (215-240 g) were obtained from Saitama Experimental Animals Supply Co., Ltd. (Saitama, Japan). Rats were housed three per cage with free access to commercial chow and tap water, and were maintained on a 12-h dark/light cycle (8:00 a.m.-8:00 p.m. light) in an air-controlled room (temperature, 24.5Ϯ1°C; humidity, 55Ϯ5%). All animal care and experimentation were conducted according to the guidelines of the Tokyo University of Science.
For the single-dose group, rats were administered flutamide at a dose of 100 mg/kg (5 ml/kg) suspended in 0.5% methylcellulose, after they had received the vehicle (0.5% methylcellulose) alone once daily for 4 d. For the repeateddose group, rats were administered flutamide once daily for 5 d at a dose of 10 mg/kg (5 ml/kg) suspended in 0.5% methylcellulose. Control rats received the vehicle alone (5 ml/kg) once daily for 5 d.
Before [ 3 H]TCA administration, rats were anesthetized with ether, and the common bile duct, femoral vein and femoral artery were cannulated with polypropylene tubing (outer diameter, 0.6 mm, 0.8 mm, and 0.8 mm, respectively). After surgery, animals were kept under heating lamp to maintain body temperature. Bile was collected during successive 10 min intervals in pre-weighed tubes, and bile flow was calculated based on the weight of the samples. A bolus of 80 nmol/kg TCA containing 1 mCi/ml animals were euthanized by exsanguination, and the liver was removed, weighed and homogenized. Plasma was quickly separated from blood by centrifugation. All samples were kept on ice until required.
HPLC Analysis of Flutamide and Hydroxyflutamide
For the quantitation of flutamide and hydroxyflutamide, aliquots of plasma and liver homogenate were mixed with 2 volumes of methanol (v/v for plasma, w/v for liver), and left on ice for 30 min. The precipitated proteins were removed by centrifugation (13000 g, 10 min), and a 10 ml aliquot of the supernatant was directly injected to the HPLC instrument. HPLC analyses were carried out on an Alliance system (Waters, Milford, MA, U.S.A.) consisting of the 2690 separation module, and the 2487 dual absorbance detector (300 nm), controlled with Empower software (Waters, Milford, MA, U.S.A.). A 250ϫ4.6-mm i.d. Mightysil RP-18 GP Aqua column (Kanto Chemical, Tokyo, Japan) was used for analysis. The mobile phase consisted of 50% water and 50% acetonitrile and was delivered at a flow rate of 1 ml/min at 40°C. Calibration curves were linear from 0.1 to 100 mM for both flutamide and hydroxyflutamide, and the coefficients of variation were less than 15 %.
Hepatic RNA Extraction and Semi-Quantitative PCR mRNAs of rBsep and Na ϩ -taurocholate cotransporting polypeptide (Ntcp) in liver were quantitated by means of a semi-quantitative PCR method. Total RNA was prepared from the liver using Isogen (Wako Pure Chemical Industries, Tokyo, Japan). The total RNA content was determined by measuring the absorbance at 260 nm. mRNA level in liver was analyzed by means of semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). Singlestranded cDNAs were constructed using an oligo(dT) primer (Invitrogen Corp., Carlsbad, CA, U.S.A.) and Improm-II TM reverse transcriptase (Promega). These cDNAs provided templates for PCRs using specific primers (rBsep: 5Ј-CG-GAATTCACAGCATTACAGCTCATTCAG-3Ј; 5Ј-ACGC-GTCGACTCACACAGCTACTCCATGCTCAAA-3Ј, rNtcp: 5Ј-GGAGACCTTAAGGACAAGGTG-3Ј; 5Ј-ATGCTGAT-GGTGCGTCTG-3Ј, G3PDH: 5Ј-TGAAGGTCGGTGTGA-ACGGATTTGGC-3Ј; 5Ј-CATGTAGGCCATGAGGTCCAC-CAC-3Ј, respectively). The PCR conditions were: denaturation at 94°C for 30 s, annealing at 58-62°C for 30-60 s, and elongation at 72°C for 30 s in the presence of deoxynucleotides (dNTPs) and Ex Taq polymerase (Takara Shuzo Co. Ltd., Tokyo). Annealing time and temperature were changed as required, depending on the genes. The PCR cycle numbers were titrated for each primer pair to confirm that amplification was performed within a linear range. PCR products were analyzed by 2% agarose gel (w/v) electrophoresis and the gels were stained with ethidium bromide for visualization. mRNA levels were quantified by using light capture (Atto Co., Tokyo). PCR amplification data were normalized with respect to glyceraldehyde-3-phosphate dehydrogenase (G3PDH).
Statistical Analysis Statistical significance was determined with Student's t test or by analysis of variance (ANOVA) followed by Dunnett's test, and a p value less than 0.05 was considered statistically significant.
RESULTS
Inhibitory Effect of Flutamide and Hydroxyflutamide on BSEP-Mediated Taurocholic Acid Transport in Vitro
To examine the involvement of BSEP in flutamide-induced cholestasis, the inhibitory effects of flutamide and hydroxyflutamide on BSEP were investigated. The ATP-dependent uptake of [ 3 H]TCA by hBSEP-expressing membrane vesicles increased over 10 min, and the uptake at 2 min was taken as the initial uptake, since the increase was linear up to this time point (data not shown). Uptake of TCA was inhibited by cyclosporine A (1 mM), the positive control, showing that specific uptake of TCA by BSEP can be evaluated by the method used in the present study. Flutamide inhibited ATPdependent [ 3 H]TCA uptake in a concentration-dependent manner from 1 to 100 mM, and the estimated IC 50 value was 48.3Ϯ9.1 mM (Fig. 1) . On the other hand, hydroxyflutamide was not inhibitory up to 100 mM. Similar results were obtained in rBsep-expressing membrane vesicles (38% of control at 100 mM flutamide, data not shown). Furthermore, we checked the reversibility of the inhibitory effect of flutamide and hydroxyflutamide on BSEP by examining the influence of pretreatment with them upon TCA transport. The inhibitory effect of flutamide on uptake of [ 3 H]TCA by hBSEP-expressing membrane vesicles that had been preincubated with flutamide for 30 min was not significantly different from that in the case of membrane vesicles that had not been preincubated with flutamide (Fig. 2) . There was also no pretreatment effect in the case of hydroxyflutamide (Fig. 2) .
Effect of Flutamide on Biliary Excretion of Taurocholic Acid in Vivo
The cholestatic effect of a single dose and repeated doses of flutamide was examined in rats. Figure 3 shows the time course of cumulative biliary excretion and the biliary excretion rate of bolus-injected [ 3 H]TCA. In both the single-dose group (100 mg/kg flutamide) and the repeateddose group (10 mg/kg flutamide for 5 d), the biliary excretion rate of [ 3 H]TCA was significantly decreased for the initial 10 min. Subsequently, however, the cumulative biliary excretions of [ 3 H]TCA in both the single-dose group and the repeated-dose group were comparable with that of the control group. There was no significant difference in plasma concentration profiles of [ 3 H]TCA among the 3 groups (Fig. 4) , and the values of area under the curve (AUC), distribution volume, and total clearance showed no significant inter-group Table 1) .
The plasma and liver concentrations of flutamide and hydroxyflutamide were also determined at the same time. One hour after [ 3 H]TCA injection (4 h after flutamide dosing) in the single-dose group, the plasma and liver concentrations of flutamide were 16.8 mM and 62.6 nmol/g of liver, respectively, and those of hydroxyflutamide were 28.3 mM and 932 nmol/g of tissue, respectively (Table 2 ). In the case of the repeateddose group, the plasma and liver concentrations of flutamide were lower than the quantitation limit (less than 0.1 mM in plasma and 0.1 nmol/g of liver, respectively) at 1 h after [ 3 H]TCA injection (25 h after the last dose of flutamide).
Effect of Flutamide on mRNA Levels of rBsep and rNtcp in Rats
The effect of flutamide on mRNA levels of rBsep in rats treated with a single dose or repeated doses of flutamide were determined. The mRNA levels of rBsep were not significantly different among the groups (Figs. 5A, B) . In addition, there was no significant change in the mRNA levels of Ntcp, which is expressed at the basolateral membrane of hepatocytes, and is involved in the transport of TCA from portal blood into the liver (Figs. 5A, B) .
DISCUSSION
Cholestasis, defined as impairment of bile formation, is accompanied with retention of bile salts, which can themselves cause hepatic injury and cholestasis. 11, 12) Several drugs such as troglitazone, bosentan, and cyclosporine A induce cholestatic hepatitis, probably by inhibiting BSEP-mediated taurocholic acid transport. [15] [16] [17] Fattinger et al. concluded that in vitro screening for BSEP inhibition can adequately predict the effects of drugs on bile salt serum levels in in vivo animal studies, and that both BSEP inhibition and increased serum bile salt levels in preclinical animal studies are indicative for the development of drug-induced cholestatic liver injury in humans. Therefore, we evaluated the inhibitory effects of flutamide and its major metabolite, hydroxyflutamide, on BSEP-mediated taurocholic acid (TCA) transport.
By in vitro transport experiments, we found that flutamide inhibited BSEP-mediated TCA transport, with an IC 50 of approximately 50 mM (Fig. 1) , while hydroxyflutamide was not inhibitory up to 100 mM. Since the inhibition constant (K i value) of flutamide and hydroxyflutamide for androgen receptor is 1450 and 205 nM, respectively, 25) and plasma concentration of hydroxyflutamide is higher than that of flutamide, 24) the pharmacological effect of flutamide can be largely attributed to hydroxyflutamide. Therefore, the pharmacological effect of flutamide can be maintained without the inhibitory effect on Bsep. Next, we examined whether the inhibitory effect of flutamide on BSEP-mediated TCA transport is relevant in the clinical situation. It was reported that the plasma concentration of flutamide in rats reached approximately 1 mM after administration of flutamide orally at a dose of 15 mg/kg, 26) and the liver-to-plasma concentration ratio (K p value) of flutamide is approximately 5 (basic product information of flutamide Odyne, Nippon Kayaku Co., Ltd., Tokyo, Japan). Based on these reports, we administered Wistar rats were orally administered flutamide, and plasma and liver samples were obtained at 1 h after bolus injection of 100 mg/kg flutamide as a single dose in order to obtain a liver concentration of flutamide close to the IC 50 value for BSEP, even though this dose is significantly higher than the clinical dose. In addition, to model the clinical situation, we administered 10 mg/kg of flutamide daily for 5 d (repeateddose group), since this is close to the clinical dose (375 mg/d). In the flutamide-treated rats, the biliary excretion rate of [ 3 H]TCA was decreased in the first 10 min in both the single-dose group and repeated-dose group (Fig. 3) . Since the cumulative biliary excretion of [ (Fig. 3) (Fig. 4, Table 1 ), it was suggested that the biliary excretion rate of [ 3 H]TCA was decreased due to a change in the efflux process from hepatocytes into bile, but not in the uptake process from blood into hepatocytes. Therefore, it was demonstrated that flutamide may cause a decrease in the biliary excretion rate of [ 3 H]TCA by inhibiting BSEP. For further understanding of flutamide-induced cholestasis, total bile acids concentrations in plasma, bile, and liver should be measured after flutamide treatment.
In the single-dose group, the flutamide concentration in liver (approx. 60 nmol/g of tissue) reached a level close to the IC 50 value for BSEP-mediated TCA uptake (approx. 50 mM) at 4 h after flutamide administration (Fig. 1, Table 2 ). However, in the repeated-dose group, the apparent flutamide concentration in liver was not high enough to inhibit BSEP (below 0.1 nmol/g of tissue), even though cholestasis was similar to that in the single-dose group. This apparent observation might be explained by irreversible inhibition by flutamide. There are reports of transporters being inhibited by such as 4,4Ј-diisothiocyanato-stilbene-2,2Ј-disulphonic acid (DIDS), which is an irreversible inhibitor of monocarboxylate transporter in rat erythrocytes. 27) When erythrocytes were preincubated with DIDS, L-lactate transport into rat erythrocytes was still reduced, even when DIDS was washed out by replacing the uptake medium with DIDS-free medium. So, it is considered in the case of irreversible inhibitors that their inhibitory effects will be observed when the apparent inhibitor concentration in tissues is lower than IC 50 value obtained without preincubation. Therefore, we investigated the preincubation effect of flutamide and hydroxyflutamide on BSEP. However, neither flutamide nor hydroxyflutamide was an irreversible inhibitor of BSEP (Fig. 2) . Accordingly, the observation that the retention of biliary excretion of [ 3 H]TCA was observed at the apparent concentration lower than IC 50 value against BSEP was not explained by irreversible inhibition.
Flutamide-induced hepatotoxicity is ameliorated by ursodeoxycholic acid (UDCA), which is a ligand of farnesoid X receptor (FXR). 19, 20) The FXR plays an important role in maintaining bile acid homeostasis by regulating key genes involved in bile acid synthesis, metabolism and transport, such as CYP7A1, UGT2B4, BSEP, NTCP, apical sodium bile acid cotransporter (ASBT), and organic solute transporter (OST) alpha-OSTbeta in humans. 28 ) Therefore, it may be possible that changes in the expression levels of these genes are involved in flutamide-induced cholestasis. In this study, since we measured the biliary excretion of bile acids after bolus injection of [ 3 H]TCA, enzymes which are involved in synthesis and/or metabolism of bile acids, such as CYP7A1 and UGT2B4, are irrelevant. Furthermore, mRNA level of rBsep and rat Ntcp were not changed (Fig. 5) . Accordingly, although the change of their protein levels cannot be denied, flutamide is not likely to affect at least the mRNA levels of these transporters. Therefore, Bsep might not play a major role in flutamide-induced cholestasis in repeated-dose group.
In this study, we focused on the effect of flutamide itself and hydroxyflutamide, but not other metabolites such as FLU-1, FLU-3, and their glucuronides, since no consistent differences were found in serum levels of these metabolites between patients with normal function and those suffering hepatic dysfunction. 24) Furthermore, a similar pattern of the profile of flutamide metabolites was observed in the case of treatment with or without UDCA, 24) which is known to be beneficial for flutamide-induced hepatotoxicity. 19) However, it is possible that these metabolites inhibit Bsep-mediated bile acids transport. Therefore, these metabolites might be involved in flutamide-induced cholestasis in repeated-dose group. For further understanding of flutamide-induced cholestasis, inhibitory effect of these metabolites on Bsep should be evaluated.
The plasma concentration of flutamide reached 0.4 mM after administration of 250 mg three times a day for 9 d in normal geriatric volunteers. 29) Since the K p value of flutamide is 5.9 in liver (Table 2) , the hepatic concentration would be approx. 2.4 mM, assuming that the K p value of flutamide in human liver is similar to that in rat liver. At this concentration, flutamide would inhibit BSEP-mediated bile acid transport by about 5%. However, if the metabolism of flutamide was reduced, e.g., by SNPs, drug-drug interactions, or altered expression of related genes, the flutamide concentration in liver might become high enough to exert an inhibitory effect on BSEP, since flutamide is extensively metabolized in the liver.
In conclusion, we found that flutamide, but not its major metabolite hydroxyflutamide, inhibits BSEP-mediated TCA transport. In addition, flutamide did not affect the mRNA level of rBsep. Accordingly, though the IC 50 value is lower than normal clinical concentration of flutamide in liver, the direct inhibition of BSEP may contribute in part to the occurrence of flutamide-induced cholestatic hepatitis.
